Treatment with pioglitazone induced significant, reversible mitral regurgitation

Mozhgan Dorkhan¹ , Magnus Dencker² and Anders Frid¹

¹Department of Clinical Sciences, Division of Diabetes & Endocrinology, Lund University, Malmö University Hospital, Malmö, Sweden

²Department of Clinical Sciences, Unit of Clinical Physiology and Nuclear Medicine, Lund University, Malmö University Hospital, Malmö, Sweden

author email corresponding author email

Cardiovascular Diabetology 2008, 7:12doi:10.1186/1475-2840-7-12


Published:	30 April 2008

Abstract

There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.